Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jaktinib vs Hydroxycarbamide in Myelofibrosis
NCT04617028Phase 3Completed
- Sponsor
- Zelgen
- Start
- Feb 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of jaktinib in myelofibrosis (MF), sponsored by Zelgen. Started Feb 2021; status: completed.
02
Drugs
jaktinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04617028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04617028.